August 1, 2023

Former Bristol-Myers Squibb, Amgen Senior Executive Will Partner with Strategy Consulting Firm in Support of its Pharma Client Portfolio

Numerof & Associates announced today a Collaborative Services Agreement with Koios Enterprises and Consulting. As part of that agreement, Michael L. Ryan, PharmD, will serve as an executive advisor with the healthcare strategy firm. In this role, the former Bristol-Myers Squibb and Amgen senior executive will work collaboratively with the Numerof team to advise selected pharmaceutical clients on strategy and planning, market access, policy analysis, and evidence generation, among other services.

“Numerof & Associates is an established brand in the global healthcare industry with a stellar 30-year reputation for bringing customized, high-value cutting edge solutions and unique perspectives to its clients that are critical in today’s market,” said Ryan. “They’re also experts at developing the infrastructure needed to design and support evolving business models—including new processes, capabilities, analytics, and the internal alignment needed to ensure success. I’m excited to collaborate with their team on the important work that lies ahead.”

Dr. Ryan retired in March from Bristol-Myers Squibb (BMS), where he was Senior Vice President in charge of US and Worldwide Value, Access, Pricing, and HEOR for the company’s $46 billion portfolio. At BMS, he led over 1,600 staff across 64 countries and served on executive leadership committees governing commercial strategy, business development, and other critical areas. Before joining BMS, Ryan spent 16 years at Amgen, where he held Vice President and General Manager roles, most recently overseeing US Reimbursement, Value, and Access and previously owning the P&L and US Sales and Marketing for Nephrology. Ryan also spent 20 years in academic healthcare leadership roles at the University of Pittsburgh and the University of Michigan. He has published extensively and served on the boards of organizations such as PhRMA, BIO, and the National Pharmaceutical Council.

“I’ve worked closely with Mike Ryan for more than a decade. His visionary leadership and successful track record in managing market access, pricing, and complex policy challenges across the globe is simply unparalleled,” said Rita Numerof, PhD, President, Numerof & Associates. “We share the same passion for anticipating where global and regional markets are going, and developing the solutions needed to help companies navigate fundamental change in the face of economic and regulatory pressures. We are also committed to helping industry leaders ensure they can continue to innovate and bring new life-saving therapies to patients.”

Dr. Ryan is the founder of Koios Enterprises and Consulting, a firm that brings leading capabilities in value evidence identification and generation, healthcare policy simulation, and impact analysis to the challenges pharmaceutical companies face in global markets. His consulting services will be offered exclusively through Numerof & Associates.

“With Koios, Mike brings a wealth of leading insights and global market expertise that will compliment and augment our core capabilities,” said Michael Abrams, MA, Managing Partner, Numerof & Associates. “Together this collaboration will accelerate our clients’ competitive standing in their chosen markets.”

About Numerof & Associates

Numerof & Associates is a strategy consulting firm that develops customized, market-based solutions for strategic and operational challenges of organizations in industries undergoing significant transition. Working globally across the healthcare industry with clients in delivery, pharmaceuticals, medical devices and diagnostics, payers, and policy, Numerof brings a unique cross-disciplinary approach to a broad range of engagements designed to sharpen strategic focus, increase revenues, reduce costs and risk, and enhance customer value. Visit us at

About Koios Enterprises & Consulting (Koios E&C)

Founded by Michael Ryan, Koios E&C leverages industry leading insights and knowledge of worldwide healthcare and policy trends, along with a focus on evidence generation and value, to provide strategic consultation and customized innovative pricing and access solutions across the product lifecycle that are tailored to reflect the current and future holistic value of your products. Visit us at